ArticleGenes2022

Loss of Heterozygosity in the Tumor DNA of De Novo Diagnosed Patients Is Associated with Poor Outcome for B-ALL but Not for T-ALL.

Natalya Risinskaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.